论文部分内容阅读
目的：研究子宫恶性中胚叶混合瘤ｐ５３、ＥＧＦＲ和Ｋｉ－６７抗原的表达及与肿瘤临床分期、组织学分级和预后的关系。方法：用免疫组化Ｓ－Ｐ法对２１例子宫恶性中胚叶混合瘤的存档资料作染色观察。结果：ｐ５３、ＥＧＦＲ和Ｋｉ－６７抗原的阳性表达率分别为６１．９％、６１．９％和７１．４％。临床分期Ⅱ～Ⅳ期肿瘤（１０／１２）的ｐ５３阳性表达率明显高于Ⅰ期肿瘤（３／９）（Ｐ＜０．０５）、肿瘤癌性成分Ⅱ级的ｐ５３阳性表达高于Ⅰ期（Ｐ＜０．０５）。６例在１年内死亡的病例，其中５例ｐ５３阳性染色，而５例生存２年以上的肿瘤ｐ５３免疫染色全部阴性，两组比较（Ｐ＜０．０５）。肉瘤成分Ⅲ级的ＥＧＦＲ阳性率高于Ⅱ级（Ｐ＜０．０５），除此而外，ＥＧＦＲ和Ｋｉ－６７的表达和肿瘤分期、预后均无相关性。结论：肿瘤的ｐ５３表达具有预后意义
Objective: To study the expression of p53, EGFR and Ki-67 antigen in malignant mesobladder mixed tumor and its relationship with clinical stage, histological grade and prognosis. Methods: The immunohistochemical S-P method in 21 cases of uterine malignant mesodermal mixed tumor archive data for staining. Results: The positive rates of p53, EGFR and Ki-67 antigen were 61.9%, 61.9% and 71.4% respectively. The positive expression rate of p53 in clinical stage Ⅱ ~ Ⅳ tumors (10/12) was significantly higher than that in stage Ⅰ tumors (3/9) (P <0.05). The positive expression of p53 in grade Ⅱ tumors was higher than that in stage Ⅰ (P <0.05). Of the 6 patients who died in one year, 5 were positive for p53, while 5 of the 5 patients who survived for more than 2 years were negative for p53 immunostaining. The two groups were compared (P <0.05). The positive rate of EGFR in grade Ⅲ of sarcoma was higher than that in grade Ⅱ (P <0.05). In addition, the expression of EGFR and Ki-67 had no correlation with tumor stage and prognosis. Conclusion: The p53 expression in tumor has prognostic significance